Skip to main content
Fig. 2 | Health and Quality of Life Outcomes

Fig. 2

From: Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial

Fig. 2

Percent of patients with improvements in FACT-Leu subscales (Kaplan-Meier analysis). a, PWB; b, S/FWB; c, LeuS; d, EWB; e, FWB. EWB emotional well-being, FACT-Leu Functional Assessment of Cancer Therapy–Leukemia, FWB functional well-being, LeuS leukemia-specific symptoms, PWB physical well-being, S/FWB social/family well-being

Back to article page

Health and Quality of Life Outcomes

ISSN: 1477-7525

Contact us